TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23582153

Group type: EXPERIMENTAL
Intervention: Mechanically evoked itch stimulation on the face
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mechanically evoked itch stimulation on the arm
Number of subjects: 0

Group type: COMPARATOR
Intervention: Histamine H1-receptor antagonists
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Discontinuation of stimulation at 90 seconds
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Touch-alloknesis in adjacent skin area
Number of subjects: 0
Study: 21790761

Group type: EXPERIMENTAL
Intervention: Pastured regime
Number of subjects: 16

Group type: COMPARATOR
Intervention: Stabled regime
Number of subjects: 16
Study: 19846743

Group type: EXPERIMENTAL
Intervention: Androgen replacement therapy (ART) with 1.5 mg methyl testosterone for 1 year
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 17043732

Group type: EXPERIMENTAL
Intervention: Lithium carbonate 885 mg/day for 2 weeks (Group III)
Number of subjects: 267

Group type: COMPARATOR
Intervention: Radioiodine therapy (all groups)
Number of subjects: 267

Group type: COMPARATOR
Intervention: Radioiodine therapy (Group II)
Number of subjects: 267
Study: 14560493

Group type: EXPERIMENTAL
Intervention: Olanzapine (10‐20 mg)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Perphenazine (8‐40 mg)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 95

Group type: COMPARATOR
Intervention: Perphenazine
Number of subjects: 95
Study: 11099366

Group type: EXPERIMENTAL
Intervention: 6.9% CHO‐electrolyte solution (CE)
Number of subjects: 9

Group type: COMPARATOR
Intervention: CHO‐ and electrolyte‐free sweetened placebo (PL)
Number of subjects: 9
Study: 8981119

Group type: EXPERIMENTAL
Intervention: i.m. pFSH alone (group pFSH)
Number of subjects: 440

Group type: COMPARATOR
Intervention: i.m. pFSH and i.m. HMG (group HMG-1)
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: s.c. FSH-HP alone (group FSH-HP)
Number of subjects: 440

Group type: COMPARATOR
Intervention: s.c. FSH-HP and i.m. HMG (group HMG-2)
Number of subjects: 440
Study: 1585842

Group type: EXPERIMENTAL
Intervention: RESTRICTED DIET (800 kcal/day)
Number of subjects: 5

Group type: COMPARATOR
Intervention: NORMAL DIET (3,000 kcal/day)
Number of subjects: 5
Study: 6363398

Group type: EXPERIMENTAL
Intervention: Cranial electrotherapy stimulation (CES)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 60
Study: 31247643

Group type: EXPERIMENTAL
Intervention: Acute cold stress
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Chronic cold stress
Number of subjects: 192

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 192
Study: 29618599

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg/d (ATV10)
Number of subjects: 10001

Group type: COMPARATOR
Intervention: Atorvastatin 80 mg/d (ATV80)
Number of subjects: 10001

Group type: EXPERIMENTAL
Intervention: Atorvastatin (both doses)
Number of subjects: 10001
Study: 27507151

Group type: EXPERIMENTAL
Intervention: Self-rating items without qualifiers
Number of subjects: 659

Group type: COMPARATOR
Intervention: Self-rating items with qualifiers
Number of subjects: 659

Group type: COMPARATOR
Intervention: Self-rating items related to anatomy with qualifiers
Number of subjects: 659
Study: 24486636

Group type: EXPERIMENTAL
Intervention: Group phone-based counseling
Number of subjects: 210

Group type: COMPARATOR
Intervention: Mail-based newsletter
Number of subjects: 210
Study: 22676819

Group type: EXPERIMENTAL
Intervention: Diode laser (gallium aluminum arsenide) at 808 nm, 1 W
Number of subjects: 20

Group type: COMPARATOR
Intervention: Er:YAG laser at 2,940 nm, 1 W
Number of subjects: 20
Study: 20206052

Group type: EXPERIMENTAL
Intervention: Femoral nerve block (FNB)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control groups with multimodal pain regimens
Number of subjects: 13

Group type: COMPARATOR
Intervention: Patient satisfaction
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: FNB
Number of subjects: 13
Study: 17095263

Group type: EXPERIMENTAL
Intervention: 2% lidocaine with 1:100,000 epinephrine buccal infiltration during each of the 5 phases of the menstrual cycle for groups 1 and 2; randomly selected day for group 3.
Number of subjects: 30
Study: 15866643

Group type: EXPERIMENTAL
Intervention: Alendronate (70 mg/week) with vitamin D and calcium
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (vitamin D and calcium only)
Number of subjects: 25
Study: 12060505

Group type: EXPERIMENTAL
Intervention: Fluconazole, 150 mg capsules, single dose repeated weekly for 2 weeks
Number of subjects: 128

Group type: COMPARATOR
Intervention: Ketoconazole, 200 mg tablets, single dose repeated weekly for 2 weeks
Number of subjects: 128
Study: 11158921

Group type: EXPERIMENTAL
Intervention: Resistance exercise training for 3 months
Number of subjects: 39

Group type: COMPARATOR
Intervention: Nonintervention (control)
Number of subjects: 39
Study: 9553546

Group type: EXPERIMENTAL
Intervention: Cemented stems
Number of subjects: 200

Group type: COMPARATOR
Intervention: Noncemented stems
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Cemented stems (matched pairs)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Noncemented stems (matched pairs)
Number of subjects: 200
Study: 8184812

Group type: EXPERIMENTAL
Intervention: lovastatin (40 mg/day)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: pravastatin (40 mg/day)
Number of subjects: 24

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: lovastatin and pravastatin
Number of subjects: 24
Study: 2453699

Group type: EXPERIMENTAL
Intervention: Combination of antiarrhythmic agents (quinidine, etmozin, disopyramide, mexitil, and allapinine)
Number of subjects: 24
Study: 29750926

Group type: EXPERIMENTAL
Intervention: Dedicated postpartum IUD inserter
Number of subjects: 500

Group type: COMPARATOR
Intervention: Modified Kelly placental forceps
Number of subjects: 500
Study: 26582645

Group type: EXPERIMENTAL
Intervention: Pretreatment serum d-2-hydroxyglutarate (D2HG) levels
Number of subjects: 84
Study: 25705952

Group type: EXPERIMENTAL
Intervention: Ablative fractional 10,600‐nm CO2 laser treatment (3 treatments at 8-week intervals)
Number of subjects: 25
Study: 23901675

Group type: EXPERIMENTAL
Intervention: Physical therapy for 4 weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 24
Study: 20630042

Group type: EXPERIMENTAL
Intervention: Iron sucrose (600 mg IV)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 200
Study: 18234127

Group type: EXPERIMENTAL
Intervention: Brief high-impact unilateral exercises
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control leg (no intervention)
Number of subjects: 0
Study: 16603135

Group type: EXPERIMENTAL
Intervention: High-dose acute tryptophan depletion
Number of subjects: 19

Group type: COMPARATOR
Intervention: Low-dose acute tryptophan depletion
Number of subjects: 19
Study: 12595913

Group type: EXPERIMENTAL
Intervention: Moclobemide (300 to 600 mg, divided in 2 to 3 doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Moclobemide (600 to 900 mg/d)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Moclobemide
Number of subjects: 0
Study: 10963246

Group type: EXPERIMENTAL
Intervention: HIV‐1 voluntary counselling and testing (VCT)
Number of subjects: 3706

Group type: COMPARATOR
Intervention: Basic health information
Number of subjects: 3706
Study: 8991564

Group type: EXPERIMENTAL
Intervention: ECM proteins (collagen I, collagen IV, fibronectin)
Number of subjects: 14

Group type: COMPARATOR
Intervention: OKT3 alone
Number of subjects: 14
Study: 1467155

Group type: EXPERIMENTAL
Intervention: Oral magnesium supplementation (magnesium pyrrolidone carboxylic acid) at a dose of 360 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ritodrine plus placebo
Number of subjects: 0
Study: 29338141

Group type: EXPERIMENTAL
Intervention: Fascia iliaca compartment block (FIB)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Femoral nerve block
Number of subjects: 100
Study: 27050699

Group type: EXPERIMENTAL
Intervention: Tretinoin (0.25%) after 30% SA peel
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Retinol (0.25%) after 30% SA peel
Number of subjects: 20

Group type: COMPARATOR
Intervention: Tretinoin (0.25%)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Retinol (0.25%)
Number of subjects: 20
Study: 24166742

Group type: EXPERIMENTAL
Intervention: Flunarizine 10 mg daily along with betahistine 16 mg and paracetamol 1 gm during episodes
Number of subjects: 48

Group type: COMPARATOR
Intervention: Betahistine and paracetamol during episodes
Number of subjects: 48
Study: 22906860

Group type: EXPERIMENTAL
Intervention: Resin-based composites (bisphenol-A-diglycidyl-dimethacrylate-composite for permanent teeth; urethane dimethacrylate-based polyacid-modified compomer for primary teeth)
Number of subjects: 534

Group type: COMPARATOR
Intervention: Amalgam
Number of subjects: 534
Study: 19777177

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with serial [(18)F] FDG-PET
Number of subjects: 66
Study: 19059048

Group type: EXPERIMENTAL
Intervention: Carraguard
Number of subjects: 6202

Group type: COMPARATOR
Intervention: Placebo (methylcellulose)
Number of subjects: 6202
Study: 16829617

Group type: EXPERIMENTAL
Intervention: MenBvac vaccine
Number of subjects: 374
Study: 14530753

Group type: EXPERIMENTAL
Intervention: Xenon sedation regimen
Number of subjects: 21

Group type: COMPARATOR
Intervention: Standard sedation regimen (intravenous propofol at 0-5 mg.kg-1.hr-1 and alfentanil 30 microg.kg-1.hr-1)
Number of subjects: 21
Study: 10968495

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids
Number of subjects: 104

Group type: COMPARATOR
Intervention: Bronchodilators without inhaled corticosteroids
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: PEF data corrected for nonlinearity of PEF meters
Number of subjects: 104
Study: 9046643

Group type: EXPERIMENTAL
Intervention: Assertion training therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: No assertion training therapy (control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pretesting
Number of subjects: 0
Study: 8325071

Group type: COMPARATOR
Intervention: Radiotherapy (50 Gy)
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy (cisplatin 50 mg/m2 and vindesine 3 mg/m2 for 2 courses)
Number of subjects: 258
Study: 3792347

Group type: EXPERIMENTAL
Intervention: Nifedipine 10 mg
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 98
Study: 29929385

Group type: EXPERIMENTAL
Intervention: Testosterone replacement therapy (1000 mg long-acting undecanoate testosterone via intramuscular injection every 3 months)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo (isotonic saline serum)
Number of subjects: 29
Study: 26139486

Group type: EXPERIMENTAL
Intervention: Goal-directed hands-on training session (Sim group)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control group (unstructured hands-on session)
Number of subjects: 59
Study: 24051107

Group type: EXPERIMENTAL
Intervention: MedGem handheld device
Number of subjects: 88

Group type: COMPARATOR
Intervention: Traditional indirect calorimeter
Number of subjects: 88
Study: 22230648

Group type: EXPERIMENTAL
Intervention: Rivastigmine 6mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rivastigmine 3mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Methamphetamine 15mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Methamphetamine 30mg
Number of subjects: 0
Study: 20188443

Group type: EXPERIMENTAL
Intervention: Individualized multifactorial intervention including in-home visits by trained nurse or physician, analytical studies, and a specifically-designed algorithm for risk detection.
Number of subjects: 328

Group type: COMPARATOR
Intervention: Routine primary care recommendations (Control group).
Number of subjects: 328
Study: 19002314

Group type: EXPERIMENTAL
Intervention: Tai chi
Number of subjects: 53

Group type: COMPARATOR
Intervention: Wait list control
Number of subjects: 53
Study: 15928719

Group type: EXPERIMENTAL
Intervention: Oral L-arginine (3.0 t.i.d p.o. for 30 days)
Number of subjects: 792

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 792

Group type: EXPERIMENTAL
Intervention: Oral L-arginine
Number of subjects: 792
Study: 12885747

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 9193

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 9193
Study: 10338173

Group type: EXPERIMENTAL
Intervention: 20 mL 1.5% mepivacaine with proximal digital pressure
Number of subjects: 20

Group type: COMPARATOR
Intervention: 40 mL 1.5% mepivacaine without digital pressure
Number of subjects: 20
Study: 8677929

Group type: EXPERIMENTAL
Intervention: Salbutamol inhalation
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 1752075

Group type: EXPERIMENTAL
Intervention: Once weekly subcutaneous administration of recombinant human erythropoietin (rHuEPO) at a starting dose of 100 U/kg body wt/week
Number of subjects: 20

Group type: COMPARATOR
Intervention: Twice weekly subcutaneous administration of recombinant human erythropoietin (rHuEPO) at a starting dose of 100 U/kg body wt/week
Number of subjects: 20
Study: 6896963

Group type: EXPERIMENTAL
Intervention: Pneumatic tourniquet
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (no tourniquet)
Number of subjects: 48
Study: 31203097

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 92
Study: 28911144

Group type: EXPERIMENTAL
Intervention: Group 1 (G1) - empiric two-pill/week dose increase followed by subsequent pill-per-week dose adjustments
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Group 2 (G2) - ongoing adjustment based on current TSH level and LT4 dose
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Group 1 (G1)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Group 2 (G2)
Number of subjects: 33
Study: 26098373

Group type: EXPERIMENTAL
Intervention: Group Coping Power (GCP)
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Individual Coping Power (ICP)
Number of subjects: 360
Study: 23660727

Group type: EXPERIMENTAL
Intervention: Emotion arousal manipulation
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Physician communication behaviors (attending to emotion and framing the decision as the patient's)
Number of subjects: 256

Group type: COMPARATOR
Intervention: Framing no cardiopulmonary resuscitation as the norm rather than cardiopulmonary resuscitation
Number of subjects: 256

Group type: COMPARATOR
Intervention: Framing the alternative to cardiopulmonary resuscitation as 'allow natural death' rather than do not resuscitate
Number of subjects: 256
Study: 21368651

Group type: EXPERIMENTAL
Intervention: Epi/Epi/Epi
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: PCA/Epi/Epi
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: PCA/Epi/PCA
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: PCA/GA/PCA
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control
Number of subjects: 65
Study: 19678751

Group type: EXPERIMENTAL
Intervention: Prescription dose NAPSO (550 mg twice daily)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: OTC doses of NAPSO (220 mg two or three times daily)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: EC‐ASA 81 mg once daily
Number of subjects: 48
Study: 17904989

Group type: EXPERIMENTAL
Intervention: Knowledge group (results of cervical length and fetal fibronectin available)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard group (blinded to cervical length and fetal fibronectin)
Number of subjects: 100
Study: 12711264

Group type: EXPERIMENTAL
Intervention: Internal attention (high speech anxious individuals)
Number of subjects: 0

Group type: COMPARATOR
Intervention: External attention (low speech anxious individuals)
Number of subjects: 0
Study: 10919685

Group type: EXPERIMENTAL
Intervention: HFA 134a pMDI
Number of subjects: 119

Group type: COMPARATOR
Intervention: CFC pMDI
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Overall analysis of HFA 134a and CFC pMDI
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Secondary efficacy variables
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Morning serum cortisol levels
Number of subjects: 119
Study: 8873539

Group type: EXPERIMENTAL
Intervention: Clonidine (2 micrograms/kg orally)
Number of subjects: 297

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 297
Study: 1415367

Group type: EXPERIMENTAL
Intervention: 2.6% amino acid solution
Number of subjects: 9

Group type: COMPARATOR
Intervention: glucose dialysate
Number of subjects: 9
Study: 3842628

Group type: EXPERIMENTAL
Intervention: Hexabrix 320
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Niopam 300
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Omnipaque 300
Number of subjects: 225
Study: 29738746

Group type: EXPERIMENTAL
Intervention: SocketKAP (group B)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: SocketKAP plus anorganic bovine bone minerals (ABBM) (group C)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: SocketKAGE plus ABBM plus SocketKAP (group E)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Unassisted healing of intact sockets (group A)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Unassisted healing of sockets with dehiscence (group D)
Number of subjects: 22
Study: 26832852

Group type: EXPERIMENTAL
Intervention: AHA peeling combined with pneumatic pressure
Number of subjects: 13

Group type: COMPARATOR
Intervention: AHA peeling alone
Number of subjects: 13
Study: 24411757

Group type: EXPERIMENTAL
Intervention: Orlistat and sibutramine treatment
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Orlistat treatment
Number of subjects: 98
Study: 22643033

Group type: EXPERIMENTAL
Intervention: Paced walking to music at home for 12 weeks
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (educational information only)
Number of subjects: 41
Study: 20164112

Group type: EXPERIMENTAL
Intervention: 4 degrees C saline + magnesium
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 4 degrees C saline
Number of subjects: 0

Group type: COMPARATOR
Intervention: 37 degrees C saline
Number of subjects: 0

Group type: COMPARATOR
Intervention: 37 degrees C saline + magnesium
Number of subjects: 0
Study: 17510045

Group type: EXPERIMENTAL
Intervention: Ephedrine 75 microg kg(‐1)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Ephedrine 100 microg kg(‐1)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Ephedrine 150 microg kg(‐1)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 100
Study: 16173387

Group type: EXPERIMENTAL
Intervention: Carisolv treatment
Number of subjects: 46

Group type: COMPARATOR
Intervention: Drilling
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Both Carisolv and Drilling
Number of subjects: 46
Study: 12190173

Group type: EXPERIMENTAL
Intervention: Misoprostol (400 microg, two doses)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 10577696

Group type: EXPERIMENTAL
Intervention: 8 Gy single fraction radiotherapy
Number of subjects: 765

Group type: COMPARATOR
Intervention: Multifraction radiotherapy (20 Gy/5 fractions or 30 Gy/10 fractions)
Number of subjects: 765
Study: 8734698

Group type: EXPERIMENTAL
Intervention: Systemic antimicrobials (metronidazole or doxycycline) and locally delivered antimicrobials (metronidazole, chlorhexidine)
Number of subjects: 94
Study: 1675136

Group type: EXPERIMENTAL
Intervention: Hickman catheters
Number of subjects: 35

Group type: COMPARATOR
Intervention: Groshong catheters
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Double-lumen catheters
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Single-lumen catheters
Number of subjects: 35
Study: 6113351

Group type: EXPERIMENTAL
Intervention: Effective CNS treatment before symptoms arise
Number of subjects: 724

Group type: EXPERIMENTAL
Intervention: Prophylactic therapy
Number of subjects: 724

Group type: COMPARATOR
Intervention: Least effective CNS prophylaxis
Number of subjects: 724

Group type: EXPERIMENTAL
Intervention: CNS prophylaxis
Number of subjects: 724

Group type: EXPERIMENTAL
Intervention: Systemic chemotherapy and better general management
Number of subjects: 724
Study: 31765036

Group type: EXPERIMENTAL
Intervention: Internal mammary artery grafting to the left anterior descending artery
Number of subjects: 100
Study: 31064336

Group type: EXPERIMENTAL
Intervention: CM education intervention delivered using a website or DVD plus booklet
Number of subjects: 153

Group type: COMPARATOR
Intervention: Booklet only (Control)
Number of subjects: 153
Study: 29203503

Group type: EXPERIMENTAL
Intervention: Stimulation programme administered by parents between 37 weeks' gestation and 6 months' corrected age
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nationally recommended follow-up only (control group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stimulation programme administered by parents
Number of subjects: 0
Study: 25727578

Group type: EXPERIMENTAL
Intervention: Binocular iPad games
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Binocular iPad games (≥8 hours compliance)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sham iPad games
Number of subjects: 50
Study: 24435893

Group type: EXPERIMENTAL
Intervention: Psychosocial counselling and support lasting 8-12 months after diagnosis
Number of subjects: 330

Group type: COMPARATOR
Intervention: Follow-up only
Number of subjects: 330
Study: 21739119

Group type: EXPERIMENTAL
Intervention: Trabectedin (1.3 mg/m²)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 75
Study: 19438584

Group type: EXPERIMENTAL
Intervention: Bilastine 20 mg
Number of subjects: 683

Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg
Number of subjects: 683

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 683
Study: 17418039

Group type: EXPERIMENTAL
Intervention: Mild hypothermia (cooled to 32 approximately 34 degrees C) in Group GCS 7 ‐ 8
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Mild hypothermia in Group GCS 5 ‐ 6
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Mild hypothermia in Group GCS 3 ‐ 4
Number of subjects: 148

Group type: COMPARATOR
Intervention: Normothermia (control) in all groups
Number of subjects: 148
Study: 14981225

Group type: EXPERIMENTAL
Intervention: Internet support (IS)
Number of subjects: 255

Group type: COMPARATOR
Intervention: Minimal in‐person support (M‐IPS)
Number of subjects: 255

Group type: COMPARATOR
Intervention: Frequent in‐person support (F‐IPS)
Number of subjects: 255
Study: 11275934

Group type: EXPERIMENTAL
Intervention: Optimized semiautomated PISA method for quantifying MR
Number of subjects: 75